BCL2 and B-cell chronic lymphocytic leukemia: Thus, BCL-2 has become an attractive target for therapeutic strategy in cancer, as demonstrated by the recent approval of ABT-199 (VenclextaTM) in relapsed or refractory Chronic Lymphocytic Leukemia with 17p deletion.